A phase IIIb,multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed PhiladelphiaChromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (ASC4START)